rofecoxib has been researched along with Arthritis, Rheumatoid in 109 studies
Arthritis, Rheumatoid: A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this multicentre, randomised, double blind, 12 week study, patients with rheumatoid arthritis were allocated to rofecoxib 50 mg once daily (n=219), naproxen 500 mg twice daily (n=220), or placebo (n=221)." | 9.10 | Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. ( Evans, J; Hawkey, CJ; Laine, L; Quan, H; Shingo, S; Simon, T, 2003) |
| " We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis." | 9.09 | Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. ( Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Reicin, A; Schnitzer, TJ; Shapiro, D, 2000) |
| " This 8-week, double-masked, placebo-controlled trial was undertaken to assess the safety profile, tolerability, and effective dose range of once-daily rofecoxib, a COX-2-specific inhibitor, in the treatment of rheumatoid arthritis (RA)." | 9.09 | The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. ( Block, J; Bolognese, J; Dalgin, P; Ehrich, EW; Fleischmann, R; Schnitzer, TJ; Seidenberg, B; Truitt, K; Zeng, Q, 1999) |
| " Methotrexate is a disease-modifying agent with a narrow therapeutic index frequently prescribed for the management of rheumatoid arthritis." | 9.09 | Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients. ( Agrawal, NG; Bachmann, KA; Ebel, DL; Gertz, BJ; Holmes, GB; Miller, JL; Porras, AG; Redfern, JS; Sack, MR; Schwartz, JI; Wong, PH, 2001) |
| "To examine the incidence of gastrointestinal (GI) events in patients with rheumatoid arthritis (RA) after the removal of rofecoxib from the market." | 7.78 | Risk of gastrointestinal events in patients with rheumatoid arthritis after withdrawal of rofecoxib. ( Anis, AH; Colley, L; Esdaile, JM; Harvard, SS; Lacaille, D; Lynd, LD; Marra, CA; Schwenger, E, 2012) |
| "Compared with nonusers, after adjusting for age, sex, presence of RA, and history of heart disease and hypertension, patients using rofecoxib, but not celecoxib or NS NSAID, had an increased rate of edema (23." | 7.72 | Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. ( Pettitt, D; Wolfe, F; Zhao, S, 2004) |
| "Our analysis suggests that the competing risks of upper gastrointestinal toxicity and myocardial infarction shown in the VIGOR trial would project a longer life expectancy with naproxen than rofecoxib among patients with rheumatoid arthritis, except in those at low risk of myocardial infarction or at high risk of upper gastrointestinal toxicity." | 7.72 | Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis. ( Choi, HK; Kuntz, KM; Seeger, JD, 2004) |
| " In the comparative trial, rofecoxib at a dosage of 50 mg/day demonstrated similar efficacy to naproxen at a dosage of 500 mg twice daily." | 6.43 | Rofecoxib for rheumatoid arthritis. ( Fidan, DD; Frankish, RR; Garner, SE; Judd, MG; Towheed, TE; Tugwell, P; Wells, G, 2005) |
| "Rofecoxib was associated with a greater risk for MI, but the exact significance and pathophysiology of this possible relationship is unclear." | 6.41 | Rofecoxib for the treatment of rheumatoid arthritis. ( Fidan, D; Frankish, R; Garner, S; Judd, M; Towheed, T; Tugwell, P; Wells, G, 2002) |
| "Rofecoxib was associated with a greater risk for MI, but the exact significance and pathophysiology of this possible relationship is unclear." | 6.41 | Rofecoxib for the treatment of rheumatoid arthritis. ( Fidan, D; Frankish, R; Garner, S; Judd, M; Towheed, T; Tugwell, P; Wells, G, 2002) |
| "Rofecoxib has greater selectivity for COX-2 than celecoxib, meloxicam, diclofenac and indomethacin." | 6.41 | Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. ( Figgitt, DP; Matheson, AJ, 2001) |
| "Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor, now being increasingly used in place of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs)." | 5.33 | Intracranial hypertension induced by rofecoxib. ( Jacob, S; Rajabally, YA, 2005) |
| "Rofecoxib have been shown to be associated with a reduced incidence of gastric erosions on endoscopy compared to standard NSAIDs in patients with arthritis." | 5.32 | [Rofecoxib: its efficacy in rheumatoid arthritis and acute pain]. ( Morović-Vergles, J, 2003) |
| "Celecoxib was dominated by diclofenac in average-risk patients." | 5.32 | The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Krahn, M; Maetzel, A; Naglie, G, 2003) |
| "Rofecoxib is a nonsteroidal anti-inflammatory drug that is reported to act by selectively inhibiting cyclooxygenase-2." | 5.31 | Aseptic meningitis associated with rofecoxib. ( Beitz, J; Bonnel, RA; Karwoski, CB; Villalba, ML, 2002) |
| "Eight thousand seventy-six rheumatoid arthritis patients aged >or=50 years (or >or=40 on corticosteroid therapy) were randomly assigned to rofecoxib 50 mg daily or naproxen 500 mg twice daily for a median of 9 months." | 5.10 | Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. ( Bombardier, C; Brett, C; Davis, B; Hawkey, CJ; Laine, L; Reicin, A; Shapiro, D, 2002) |
| "9% per year in rheumatoid arthritis patients taking the nonselective NSAID naproxen, accounting for nearly 40% of the serious GI events that developed in these patients." | 5.10 | Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. ( Bombardier, C; Burgos-Vargas, R; Connors, LG; Hawkey, CJ; Laine, L; Reicin, A; Schnitzer, TJ; Yu, Q, 2003) |
| "In this multicentre, randomised, double blind, 12 week study, patients with rheumatoid arthritis were allocated to rofecoxib 50 mg once daily (n=219), naproxen 500 mg twice daily (n=220), or placebo (n=221)." | 5.10 | Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. ( Evans, J; Hawkey, CJ; Laine, L; Quan, H; Shingo, S; Simon, T, 2003) |
| " This 8-week, double-masked, placebo-controlled trial was undertaken to assess the safety profile, tolerability, and effective dose range of once-daily rofecoxib, a COX-2-specific inhibitor, in the treatment of rheumatoid arthritis (RA)." | 5.09 | The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. ( Block, J; Bolognese, J; Dalgin, P; Ehrich, EW; Fleischmann, R; Schnitzer, TJ; Seidenberg, B; Truitt, K; Zeng, Q, 1999) |
| " Methotrexate is a disease-modifying agent with a narrow therapeutic index frequently prescribed for the management of rheumatoid arthritis." | 5.09 | Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients. ( Agrawal, NG; Bachmann, KA; Ebel, DL; Gertz, BJ; Holmes, GB; Miller, JL; Porras, AG; Redfern, JS; Sack, MR; Schwartz, JI; Wong, PH, 2001) |
| " We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis." | 5.09 | Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. ( Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Reicin, A; Schnitzer, TJ; Shapiro, D, 2000) |
| "We know from adult randomised controlled trials that some NSAIDs, such as ibuprofen, naproxen, and aspirin, can be effective in certain chronic pain conditions." | 4.95 | Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. ( Anderson, B; Cooper, TE; Eccleston, C; Fisher, E; Wilkinson, NM, 2017) |
| "Although the published literature is limited, the data indicate that rofecoxib is an effective analgesic agent for the painful conditions in which it has been studied." | 4.81 | Rofecoxib: clinical pharmacology and clinical experience. ( Weaver, AL, 2001) |
| "To examine the incidence of gastrointestinal (GI) events in patients with rheumatoid arthritis (RA) after the removal of rofecoxib from the market." | 3.78 | Risk of gastrointestinal events in patients with rheumatoid arthritis after withdrawal of rofecoxib. ( Anis, AH; Colley, L; Esdaile, JM; Harvard, SS; Lacaille, D; Lynd, LD; Marra, CA; Schwenger, E, 2012) |
| "During the review process of the Vioxx Gastrointestinal Outcomes Research study, it was suggested that rofecoxib might have little benefit, with regard to GI toxicity, for patients with rheumatoid arthritis not treated with corticosteroids." | 3.77 | Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation. ( Chan, FK; Graham, DY; Jewell, NP, 2011) |
| " Ischemic stroke was predicted by hypertension, myocardial infarction, low-dose aspirin, comorbidity score, Health Assessment Questionnaire score, and presence of total joint replacement, but not by diabetes, smoking, exercise, or body mass index." | 3.74 | Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. ( Hallenbeck, JM; Michaud, K; Nadareishvili, Z; Wolfe, F, 2008) |
| " We report two cases of acute psychotic syndromes with visual (Case 1 + 2) and auditory (Case 1) hallucinations under rofecoxib, a cyclooxygenase-2-inhibitor." | 3.74 | [Rofecoxib-induced psychosis]. ( Connemann, BJ; Kassubek, J; Sabolek, M; Sperfeld, AD; Unrath, A, 2007) |
| " This study evaluated average daily doses and costs of rofecoxib and celecoxib and concomitant use of gastroprotective agents (GPAs) in elderly patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in Quebec, prior to the rofecoxib withdrawal." | 3.73 | Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib? ( Chabot, I; Hunsche, E; Rahme, E; Toubouti, Y, 2006) |
| "This study assessed prescribing patterns for rofecoxib and celecoxib in the treatment of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as differences in prescribing patterns across physician specialties." | 3.72 | An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis. ( Kong, SX; Mavros, P; Mitchell, JH; Pellissier, JM; Schnitzer, TJ; Straus, WL; Watson, DJ, 2003) |
| "A total of 3639 patients with rheumatoid arthritis (RA), osteoarthritis, and fibromyalgia starting therapy of celecoxib, rofecoxib, naproxen, or ibuprofen were surveyed at 6-month intervals for up to 2." | 3.72 | Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. ( Burke, TA; Michaud, K; Wolfe, F; Zhao, SZ, 2004) |
| "A 73-year-old woman was prescribed rofecoxib 25 mg/day for rheumatoid arthritis in addition to other medications on which the patient had been stabilized." | 3.72 | Lichenoid drug eruption probably associated with rofecoxib. ( Abu-Shraie, NA; Alfadley, AA, 2004) |
| "Compared with nonusers, after adjusting for age, sex, presence of RA, and history of heart disease and hypertension, patients using rofecoxib, but not celecoxib or NS NSAID, had an increased rate of edema (23." | 3.72 | Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. ( Pettitt, D; Wolfe, F; Zhao, S, 2004) |
| "Our analysis suggests that the competing risks of upper gastrointestinal toxicity and myocardial infarction shown in the VIGOR trial would project a longer life expectancy with naproxen than rofecoxib among patients with rheumatoid arthritis, except in those at low risk of myocardial infarction or at high risk of upper gastrointestinal toxicity." | 3.72 | Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis. ( Choi, HK; Kuntz, KM; Seeger, JD, 2004) |
| "A population of 6637 patients with rheumatoid arthritis (RA) and osteoarthritis (OA) from the practices of 433 US rheumatologists completed 2 sets of detailed questionnaires concerning (1) the last 6 months in 1998 and (2) the first 6 months of 1999, generally prior to and after the release of celecoxib and rofecoxib." | 3.71 | Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthr ( Arguelles, LM; Burke, TA; Flowers, N; Pettitt, D; Wolfe, F, 2002) |
| " In the comparative trial, rofecoxib at a dosage of 50 mg/day demonstrated similar efficacy to naproxen at a dosage of 500 mg twice daily." | 2.43 | Rofecoxib for rheumatoid arthritis. ( Fidan, DD; Frankish, RR; Garner, SE; Judd, MG; Towheed, TE; Tugwell, P; Wells, G, 2005) |
| " The initial oral dosage of rofecoxib is 12." | 2.41 | [Pharma-clinics. The drug of the month. Rofecoxib (Vioxx)]. ( Scheen, AJ, 2000) |
| " Comparisons were made between patients taking rofecoxib and those taking either placebo, naproxen (an NSAID with near-complete inhibition of platelet function throughout its dosing interval), or another nonselective NSAIDs used in the development program (diclofenac, ibuprofen, and nabumetone)." | 2.41 | Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. ( Barr, E; Gertz, BJ; Konstam, MA; Reicin, A; Shapiro, D; Sperling, RS; Weir, MR, 2001) |
| " However, NSAIDs cause significant adverse upper gastrointestinal effects, including increased mortality from serious ulcer complications." | 2.41 | Selective inhibitors of COX-2--are they safe for the stomach? ( Giercksky, KE; Haglund, U; Rask-Madsen, J, 2000) |
| "Rofecoxib has greater selectivity for COX-2 than celecoxib, meloxicam, diclofenac and indomethacin." | 2.41 | Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. ( Figgitt, DP; Matheson, AJ, 2001) |
| "Celecoxib and rofecoxib have been used in Norway since 2000." | 2.41 | [A critical evaluation of side effect data on COX-2 inhibitors]. ( Pomp, E, 2002) |
| "Rofecoxib was associated with a greater risk for MI, but the exact significance and pathophysiology of this possible relationship is unclear." | 2.41 | Rofecoxib for the treatment of rheumatoid arthritis. ( Fidan, D; Frankish, R; Garner, S; Judd, M; Towheed, T; Tugwell, P; Wells, G, 2002) |
| "Rofecoxib was associated with a greater risk for MI, but the exact significance and pathophysiology of this possible relationship is unclear." | 2.41 | Rofecoxib for the treatment of rheumatoid arthritis. ( Fidan, D; Frankish, R; Garner, S; Judd, M; Towheed, T; Tugwell, P; Wells, G, 2002) |
| "Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor, now being increasingly used in place of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs)." | 1.33 | Intracranial hypertension induced by rofecoxib. ( Jacob, S; Rajabally, YA, 2005) |
| "Rofecoxib users were at a significantly increased relative risk of new onset hypertension compared with patients taking celecoxib (odds ratio [OR] 1." | 1.32 | Relationship between COX-2 specific inhibitors and hypertension. ( Avorn, J; Levin, R; Schneeweiss, S; Solomon, DH, 2004) |
| "Rofecoxib have been shown to be associated with a reduced incidence of gastric erosions on endoscopy compared to standard NSAIDs in patients with arthritis." | 1.32 | [Rofecoxib: its efficacy in rheumatoid arthritis and acute pain]. ( Morović-Vergles, J, 2003) |
| "Celecoxib was dominated by diclofenac in average-risk patients." | 1.32 | The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Krahn, M; Maetzel, A; Naglie, G, 2003) |
| "Rofecoxib is a nonsteroidal anti-inflammatory drug that is reported to act by selectively inhibiting cyclooxygenase-2." | 1.31 | Aseptic meningitis associated with rofecoxib. ( Beitz, J; Bonnel, RA; Karwoski, CB; Villalba, ML, 2002) |
| "Electrolyte disorders and acute renal failure are observed more frequently in patients with risk factors." | 1.31 | [Renal tolerance of selective inhibitors of cyclooxygenase type 2]. ( Deray, G, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (2.75) | 18.2507 |
| 2000's | 103 (94.50) | 29.6817 |
| 2010's | 3 (2.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hashimoto, H | 1 |
| Imamura, K | 1 |
| Haruta, J | 1 |
| Wakitani, K | 1 |
| Eccleston, C | 1 |
| Cooper, TE | 1 |
| Fisher, E | 1 |
| Anderson, B | 1 |
| Wilkinson, NM | 1 |
| Nadareishvili, Z | 1 |
| Michaud, K | 2 |
| Hallenbeck, JM | 1 |
| Wolfe, F | 4 |
| Graham, DY | 1 |
| Jewell, NP | 1 |
| Chan, FK | 1 |
| Marra, CA | 1 |
| Lynd, LD | 1 |
| Colley, L | 1 |
| Harvard, SS | 1 |
| Lacaille, D | 1 |
| Schwenger, E | 1 |
| Anis, AH | 1 |
| Esdaile, JM | 1 |
| Wooltorton, E | 1 |
| Budenholzer, BR | 1 |
| Garner, S | 2 |
| Fidan, D | 2 |
| Frankish, R | 2 |
| Judd, M | 2 |
| Towheed, T | 2 |
| Wells, G | 3 |
| Tugwell, P | 3 |
| Bianchi, M | 1 |
| Broggini, M | 1 |
| Laine, L | 5 |
| Bombardier, C | 5 |
| Hawkey, CJ | 6 |
| Davis, B | 3 |
| Shapiro, D | 4 |
| Brett, C | 1 |
| Reicin, A | 5 |
| Geusens, PP | 1 |
| Truitt, K | 2 |
| Sfikakis, P | 1 |
| Zhao, PL | 1 |
| DeTora, L | 1 |
| Shingo, S | 2 |
| Lau, CS | 1 |
| Kalla, A | 1 |
| Tate, G | 1 |
| Meyer, Ch | 1 |
| Gähler, R | 1 |
| Håkansson, J | 1 |
| Hochberg, MC | 4 |
| Hutchins, V | 1 |
| Hutchins, B | 1 |
| Einecke, D | 2 |
| Connors, LG | 1 |
| Burgos-Vargas, R | 3 |
| Schnitzer, TJ | 5 |
| Yu, Q | 1 |
| Harley, C | 1 |
| Wagner, S | 1 |
| Lehmann, FS | 1 |
| Gyr, N | 1 |
| Simon, T | 1 |
| Quan, H | 1 |
| Evans, J | 1 |
| Spiegel, BM | 1 |
| Targownik, L | 1 |
| Dulai, GS | 1 |
| Gralnek, IM | 1 |
| Woods, JM | 1 |
| Mogollon, A | 1 |
| Amin, MA | 1 |
| Martinez, RJ | 1 |
| Koch, AE | 1 |
| Maetzel, A | 1 |
| Krahn, M | 1 |
| Naglie, G | 1 |
| Layton, D | 1 |
| Heeley, E | 1 |
| Hughes, K | 1 |
| Shakir, SA | 1 |
| Chiolero, A | 1 |
| Maillard, MP | 1 |
| Burnier, M | 1 |
| Kojima, F | 1 |
| Naraba, H | 1 |
| Sasaki, Y | 1 |
| Beppu, M | 1 |
| Aoki, H | 1 |
| Kawai, S | 1 |
| Anderson, JJ | 1 |
| Bolognese, JA | 1 |
| Felson, DT | 1 |
| Burian, M | 1 |
| Geisslinger, G | 1 |
| Kong, SX | 1 |
| Mitchell, JH | 1 |
| Mavros, P | 1 |
| Watson, DJ | 1 |
| Pellissier, JM | 1 |
| Straus, WL | 1 |
| Burke, TA | 3 |
| Zhao, SZ | 2 |
| Gibson, L | 1 |
| Abu-Shraie, NA | 1 |
| Alfadley, AA | 1 |
| Choi, HK | 1 |
| Seeger, JD | 1 |
| Kuntz, KM | 1 |
| Morović-Vergles, J | 1 |
| Wentworth, C | 1 |
| Makuch, RW | 1 |
| Zhao, S | 1 |
| Pettitt, D | 2 |
| Solomon, DH | 1 |
| Schneeweiss, S | 1 |
| Levin, R | 1 |
| Avorn, J | 1 |
| Tran, F | 1 |
| Boggie, DT | 1 |
| Delattre, ML | 1 |
| Schaefer, MG | 1 |
| Morreale, AP | 1 |
| Plowman, BK | 1 |
| Jolly, M | 1 |
| Curran, JJ | 1 |
| Topol, EJ | 2 |
| Bannwarth, B | 1 |
| Logeart, I | 1 |
| Vergult, G | 1 |
| Dyer, C | 1 |
| Vincent, S | 1 |
| Slease, RB | 1 |
| Rocca, PV | 1 |
| Yodfat, Y | 1 |
| Karha, J | 1 |
| Jacob, S | 1 |
| Rajabally, YA | 1 |
| Garner, SE | 1 |
| Fidan, DD | 1 |
| Frankish, RR | 1 |
| Judd, MG | 1 |
| Towheed, TE | 1 |
| Giannitsis, E | 1 |
| Carné, X | 1 |
| Cruz, N | 1 |
| Palmer, K | 1 |
| Fortun, PJ | 1 |
| Lüth, P | 1 |
| Herold, M | 1 |
| Mur, E | 1 |
| Day, D | 1 |
| Furlan, A | 1 |
| Irvin, E | 1 |
| Rahme, E | 1 |
| Hunsche, E | 1 |
| Toubouti, Y | 1 |
| Chabot, I | 1 |
| Curfman, GD | 1 |
| Morrissey, S | 1 |
| Drazen, JM | 1 |
| Day, R | 2 |
| Ferraz, MB | 2 |
| Kvien, TK | 2 |
| Weaver, A | 1 |
| Shakiba, K | 1 |
| Falcone, T | 1 |
| Sabolek, M | 1 |
| Unrath, A | 1 |
| Sperfeld, AD | 1 |
| Connemann, BJ | 1 |
| Kassubek, J | 1 |
| Sukel, MP | 1 |
| van der Linden, MW | 1 |
| Chen, C | 1 |
| Erkens, JA | 1 |
| Herings, RM | 1 |
| Wall, R | 1 |
| Strickland, C | 1 |
| Jamieson, B | 1 |
| Lo, V | 1 |
| Lapner, MA | 1 |
| Stephen, WJ | 1 |
| Mielke, F | 1 |
| Schweigert, M | 1 |
| Harirforoosh, S | 1 |
| Jamali, F | 1 |
| Rehman, Q | 1 |
| Sack, KE | 1 |
| Fleischmann, R | 1 |
| Dalgin, P | 1 |
| Block, J | 1 |
| Zeng, Q | 1 |
| Bolognese, J | 1 |
| Seidenberg, B | 1 |
| Ehrich, EW | 1 |
| Infante, R | 1 |
| Lahita, RG | 1 |
| Blondon, H | 1 |
| Oliw, E | 1 |
| Wollheim, FA | 1 |
| Scheen, AJ | 1 |
| Brooks, PM | 1 |
| Day, RO | 1 |
| Giercksky, KE | 1 |
| Haglund, U | 1 |
| Rask-Madsen, J | 1 |
| Cannon, GW | 1 |
| Breedveld, FC | 1 |
| Sundy, JS | 1 |
| Adelman, A | 1 |
| Pasero, C | 1 |
| McCaffery, M | 1 |
| Matheson, AJ | 1 |
| Figgitt, DP | 1 |
| Kellner, H | 1 |
| Wildy, KS | 1 |
| Wasko, MC | 1 |
| Schwartz, JI | 1 |
| Agrawal, NG | 1 |
| Wong, PH | 1 |
| Bachmann, KA | 1 |
| Porras, AG | 1 |
| Miller, JL | 1 |
| Ebel, DL | 1 |
| Sack, MR | 1 |
| Holmes, GB | 1 |
| Redfern, JS | 1 |
| Gertz, BJ | 2 |
| Cleland, LG | 1 |
| James, MJ | 1 |
| Stamp, LK | 1 |
| Penglis, PS | 1 |
| Weaver, AL | 1 |
| Konstam, MA | 1 |
| Weir, MR | 1 |
| Sperling, RS | 1 |
| Barr, E | 1 |
| Deray, G | 1 |
| Krüger, K | 1 |
| Bonnel, RA | 1 |
| Villalba, ML | 1 |
| Karwoski, CB | 1 |
| Beitz, J | 1 |
| Pomp, E | 1 |
| Berenbaum, F | 1 |
| Flowers, N | 1 |
| Arguelles, LM | 1 |
| Silas, S | 1 |
| Clegg, DO | 1 |
| Gupta, S | 1 |
| Crofford, LJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Phase II Pilot Study of the Efficacy of FANG(30) to Treat Active Rheumatoid Arthritis in Adult Patients[NCT00749645] | Phase 2 | 60 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Pre-Emptive Analgesic Effects of a Selective COX-2 Inhibitor (Rofecoxib) in the Oral Surgery Model[NCT00026819] | Phase 2 | 150 participants | Interventional | 2001-11-30 | Completed | ||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
29 reviews available for rofecoxib and Arthritis, Rheumatoid
| Article | Year |
|---|---|
Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Arthritis, Rheumatoid; Asp | 2017 |
Rofecoxib for the treatment of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Lactones; Naproxen; Randomiz | 2002 |
Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective.
Topics: Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibito | 2002 |
[The future of peptic ulcer disease without Helicobacter].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin | 2003 |
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; | 2003 |
Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseases; Ce | 2002 |
[Clinical pharmacology of the selective COX-2 inhibitors].
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis | 2003 |
[Is there a future for COX-2 inhibitors?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase 2 I | 2004 |
Rofecoxib for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Drug Appr | 2005 |
Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP.
Topics: Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biomarkers; Cardio | 2005 |
Life after Vioxx: the clinical implications.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Clinical Tr | 2005 |
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cy | 2005 |
Clinical inquiries. Do COX-2 inhibitors worsen renal function?
Topics: Arthritis, Rheumatoid; Celecoxib; Contraindications; Cyclooxygenase 2 Inhibitors; Humans; Kidney; La | 2007 |
When to try COX-2-specific inhibitors. Safer than standard NSAIDs in some situations.
Topics: Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enz | 1999 |
Rheumatoid arthritis. New disease-modifying and anti-inflammatory drugs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthri | 2000 |
[New treatment of pain and fever in rheumatoid arthritis and arthrosis. The first cyclooxygenase-2 inhibitors show promising results].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Controlled Clinical Trial | 2000 |
[Pharma-clinics. The drug of the month. Rofecoxib (Vioxx)].
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biologi | 2000 |
Selective inhibitors of COX-2--are they safe for the stomach?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 2000 |
Efficacy of cyclooxygenase-2-specific inhibitors.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxyge | 2001 |
COX-2 inhibitors in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Digestive Sys | 2001 |
Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Tri | 2001 |
Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumat | 2001 |
COX-2 inhibition and thrombotic tendency: a need for surveillance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase I | 2001 |
Rofecoxib: clinical pharmacology and clinical experience.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Lactones; Osteoarthritis; Pa | 2001 |
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascu | 2001 |
[A critical evaluation of side effect data on COX-2 inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 2002 |
[New nonsteroidal antiinflammatory drugs in rheumatoid arthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Gastric Mucosa; Humans; L | 2002 |
Rofecoxib for the treatment of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Lactones; Naproxen; Randomiz | 2002 |
An update on specific COX-2 inhibitors: the COXIBs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 2001 |
11 trials available for rofecoxib and Arthritis, Rheumatoid
| Article | Year |
|---|---|
Anti-hyperalgesic effects of nimesulide: studies in rats and humans.
Topics: Aged; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; | 2002 |
Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adult; Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Art | 2002 |
A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase In | 2002 |
Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygen | 2003 |
Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cycl | 2003 |
Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost Savings; Cyclooxyge | 2004 |
The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Double-Blind Metho | 1999 |
[Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhi | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
[The selective Cox-2 inhibition by rofecoxib reduces risk of severe gastrointestinal complications of anti-inflammatory therapy by more than 50%].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Endoscopy, Gastrointestinal; | 2001 |
Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients.
Topics: Adult; Aged; Analysis of Variance; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Co | 2001 |
69 other studies available for rofecoxib and Arthritis, Rheumatoid
| Article | Year |
|---|---|
4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1)
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Benzenesulfonates; Cyclooxygenase 1; Cyclooxygenase | 2002 |
Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; An | 2008 |
Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2 | 2011 |
Risk of gastrointestinal events in patients with rheumatoid arthritis after withdrawal of rofecoxib.
Topics: Aged; Arthritis, Rheumatoid; British Columbia; Cohort Studies; Female; Gastrointestinal Diseases; Hu | 2012 |
What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).
Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Middle Aged; Myocardi | 2002 |
Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; | 2002 |
[No chance for pain. Rofecoxib eases not only tooth extraction].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; La | 2002 |
Central retinal vein occlusion in a patient with rheumatoid arthritis taking rofecoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Causalit | 2002 |
[Already the drug of choices in the USA. Coxibe in joint pain].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Drug Appr | 2002 |
[Financial interests characterize published reports on coxiber. Whom can we rely on?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Cel | 2002 |
COX-2 inhibitors: new drugs for the management of pain and inflammation.
Topics: Analgesics; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid | 2001 |
[No loss of effectiveness with rofecoxib. Long-term control of rheumatoid pain].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclooxyge | 2002 |
The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular D | 2003 |
[Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascu | 2003 |
Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost-Ben | 2003 |
The role of COX-2 in angiogenesis and rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cells, Cultured; Chemotaxis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2003 |
The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Canada; Cel | 2003 |
Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Chi- | 2003 |
[Selective COX 2 inhibitor rofecoxib. To "defy" the pain].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors | 2003 |
Prostaglandin E2 is an enhancer of interleukin-1beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cells, Cultured; Colforsin; Cyclic A | 2003 |
Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Auranofin; Clinical Trials as Topic; Computer Simulatio | 2003 |
An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhi | 2003 |
Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Community Health Services | 2004 |
Spanish drug editor wins case brought by Merck, Sharp Dohme.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Industry; Lactones; Liability, | 2004 |
Lichenoid drug eruption probably associated with rofecoxib.
Topics: Aged; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Drug Eruptions; Female; Humans; Lactones; Su | 2004 |
Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis.
Topics: Aged; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Decision Support Techniques; Female; Gastroi | 2004 |
[Rofecoxib: its efficacy in rheumatoid arthritis and acute pain].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibi | 2003 |
Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inh | 2004 |
Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Celecox | 2004 |
[Coxib instead of NSAID plus gastric acid inhibitor. Protection for the small intestine].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Clinical Trials a | 2004 |
Relationship between COX-2 specific inhibitors and hypertension.
Topics: Aged; Arthritis, Rheumatoid; Case-Control Studies; Celecoxib; Cyclooxygenase Inhibitors; Female; Hum | 2004 |
Chlamydial infection preceding the development of rheumatoid arthritis: a brief report.
Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chlamy | 2004 |
Failing the public health--rofecoxib, Merck, and the FDA.
Topics: Adverse Drug Reaction Reporting Systems; Advertising; Arthritis, Rheumatoid; Clinical Trials as Topi | 2004 |
[Prescribing patterns of rofecoxib in the primary care setting: results of a French survey].
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Arthritis; Arth | 2004 |
UK patients seek compensation after taking rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Compensation and Redress; Humans; La | 2004 |
Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Drug Interactions; Ep | 2002 |
The sad story of Vioxx, and what we should learn from it.
Topics: Arthritis, Rheumatoid; Drug Approval; Drug Industry; Humans; Lactones; Myocardial Infarction; Produc | 2004 |
Intracranial hypertension induced by rofecoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Hum | 2005 |
Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Drug and | 2005 |
The Vioxx fallout.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumat | 2005 |
[The medical reason for the prescription of COX-2 selective cyclo oxygenase inhibitor rofecoxib for the treatment of rheumatoid arthritis. A post-marketing surveillance study from Austria].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheu | 2005 |
Simplified search strategies were effective in identifying clinical trials of pharmaceuticals and physical modalities.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Back Pain; Clinical Trials as Topic; | 2005 |
Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; Costs and Cost Analysi | 2006 |
Expression of concern reaffirmed.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Lactones; Myocard | 2006 |
Response to expression of concern regarding VIGOR study.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Data Interpretation, Statistical; Gastrointestinal D | 2006 |
Response to expression of concern regarding VIGOR study.
Topics: Arthritis, Rheumatoid; Data Interpretation, Statistical; Gastrointestinal Diseases; Humans; Lactones | 2006 |
Tumour necrosis factor-alpha blockers: potential limitations in the management of advanced endometriosis? A case report.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 I | 2006 |
[Rofecoxib-induced psychosis].
Topics: Aged; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Female; Follow-Up Studies; Hallucinations; H | 2007 |
Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cohort Stud | 2008 |
Rofecoxib associated with diaphragm disease.
Topics: Arthritis, Rheumatoid; Constriction, Pathologic; Cyclooxygenase 2 Inhibitors; Female; Humans; Intest | 2007 |
Safe adalimumab therapy for rheumatoid arthritis in a patient with pre-existing multiple myeloma.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2008 |
Effect of inflammation on kidney function and pharmacokinetics of COX-2 selective nonsteroidal anti-inflammatory drugs rofecoxib and meloxicam.
Topics: Administration, Oral; Animals; Area Under Curve; Arthritis, Experimental; Arthritis, Rheumatoid; Cyc | 2008 |
COX-2 inhibitors. Magic bullets or merely mortal?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 2000 |
[Specific COX-2 inhibitors. Also effective in arthritis?].
Topics: Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Hum | 2000 |
COX-2 inhibitors.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenas | 2000 |
[Rheumatism therapy, from the economic viewpoint. COX-2 inhibitor as cost saving drug].
Topics: Arthritis, Rheumatoid; Celecoxib; Cost Savings; Cyclooxygenase Inhibitors; Drug Costs; Germany; Lact | 2000 |
[Therapy with rofecoxib. Decreasing risk by controlled COX-2 inhibitor administration].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Enz | 2000 |
[Stomach-saving "Coxibs". No reason for therapeutic risks].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Humans; Lactones; Peptic Ulc | 2001 |
Is rofecoxib safer than naproxen?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Do | 2001 |
Selective COX-2 inhibitors.
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; | 2001 |
[Results of the VIGOR study. Rofecoxib halves the complication rate].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Response Relationship, Dr | 2001 |
[Selective COX-2 inhibitor. Stomach protection--but not always].
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycl | 2001 |
[Elderly patient with rheumatoid arthritis. Minimizing the peptic ulcer hemorrhage risk].
Topics: Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Cycl | 2001 |
[Renal tolerance of selective inhibitors of cyclooxygenase type 2].
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents, Non-Steroida | 2001 |
[Cox-2 inhibitors in the focus. Rofecoxib as effective as the "classics"].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal | 2001 |
[Current status of COX II inhibitors in therapy of rheumatoid arthritis in comparison with conventional non-steroidal anti-inflammatory agents. Attempt at an evaluation with regard to evidence-based medicine].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; | 2001 |
Aseptic meningitis associated with rofecoxib.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Carpal Tunn | 2002 |
Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthr
Topics: Aged; Arthritis, Rheumatoid; Bias; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase 2; | 2002 |
Selective COX-2 inhibition.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 1999 |